Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)

Authors

Peter W. Andrews, University of Sheffield
Duncan Baker, Sheffield Children's NHS Foundation Trust
N Benvinisty, Hebrew University of Jerusalem
B Miranda, Biobank Andalousian Public Health System
K Bruce, Roslin Cells Ltd.
O Brustle, University of Bonn
M Choi, Ministry of Food and Drugs Safety Oosong
Young Min Choi, Seoul National University
Jeremy M. Crook, University of WollongongFollow
Paul A. de Sousa, University of Edinburgh

RIS ID

99270

Publication Details

Andrews, P. W., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Brustle, O., Choi, M., Choi, Y. -M., Crook, J. M., de Sousa, P. A. et al (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regenerative Medicine, 10 (2s), 1-44. © Copyright 2015. Future Medicine Ltd - reproduced with permission.

Additional Publication Information

Paper reproduced with permission from Future Medicine Ltd.

Abstract

In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications.